Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11607361 | 0.84 | ADRB2 (0.45) | SLC6A4SLC6A3ADRB2AOC3GABBR2 | |
| SCHEMBL15787650 | 0.82 | CYP1A2 (0.39) | TAAR1UTS2RLMNACYP2C9CYP3A4 | |
| SCHEMBL25487567 | 0.82 | SLC6A4 (0.40) | SLC6A4SLC6A3ADRB2TAAR1UTS2R | |
| SCHEMBL15787626 | 0.82 | CYP1A2 (0.39) | TAAR1UTS2RLMNACYP2C9CYP3A4 | |
| SCHEMBL11174386 | 0.80 | HRH1 (0.56) | SLC6A4SLC6A3TAAR1AOC3CYP2C9 | |
| SCHEMBL14261910 | 0.79 | SLC6A4 (0.43) | SLC6A4TAAR1AOC3SLC6A2 | |
| SCHEMBL436301 | 0.78 | UTS2R (0.40) | SLC6A4SLC6A3ADRB2UTS2RLMNA | |
| SCHEMBL5320420 | 0.78 | UTS2R (0.42) | SLC6A4SLC6A3UTS2RBRD4FFAR2 | |
| SCHEMBL6278630 | 0.78 | ATP1A1 (0.42) | SLC6A4SLC6A3ADRB2TAAR1AOC3 | |
| SCHEMBL28338266 | 0.78 | GAA (0.45) | SLC6A4SLC6A3ADRB2TAAR1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1768966-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009869-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | SLC6A4 4326/4885SLC6A3 4000/4885ADRB2 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.